<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03810417</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00083553</org_study_id>
    <nct_id>NCT03810417</nct_id>
  </id_info>
  <brief_title>Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI</brief_title>
  <official_title>Single System Double Blinded Trial to Evaluate the Effect of Pre-operative Treatment With DigiFab to Prevent Post-operative Acute Kidney Injury (AKI) in Patients at High Risk for AKI Undergoing Cardiac Bypass Graft Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass
      graft (CABG) surgery, and often requires patients to go on dialysis. In patients needing
      dialysis, the risk of dying is very high.There are no known therapies to reduce the chance of
      developing kidney damage after heart surgery. There is evidence that patients with high
      levels of a substance called ouabain have an increased risk of developing kidney damage. This
      study is testing the hypothesis that giving a medication called DigiFab to lower the ouabain
      levels will reduce the risk of developing kidney damage after heart surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blinded study investigating the role of DigiFab in patients with
      elevated risk of acute kidney injury undergoing CABG surgery. University of Maryland Medical
      Center (UMMC) and University of Maryland St Joseph Medical Center (UMSJMC) patients who are
      undergoing CABG, meet the inclusion criteria and provide consent will be enrolled in this
      study and randomized to either DigiFab arm or the placebo (vehicle) arm. The study involves a
      follow up period of 72 hours post CABG surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients undergoing coronary artery bypass surgery</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Investigational pharmacy will provide active drug or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Renal function</measure>
    <time_frame>72 hours</time_frame>
    <description>Change in glomerular filtration rate (measured by Cockcroft-Gault Formula), mL/min per 1.73 m2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for dialysis</measure>
    <time_frame>30 days</time_frame>
    <description>Number of patients with any dialysis given within 30 days of surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Digifab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Digifab intravenous</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>saline intravenous</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Digoxin Antibodies Fab Fragments</intervention_name>
    <description>Digoxin antibodies</description>
    <arm_group_label>Digifab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing coronary artery bypass surgery

          -  glomerular filtration rate &gt; 15 History of Diabetes Mellitus or GFR &lt; 60

        Exclusion Criteria:

          -  Allergy to Digifab Contrast dye within 3 days Creatinine &gt; 25% above baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen S Gottlieb</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Gottlieb, MD</last_name>
    <phone>4103288788</phone>
    <email>sgottlie@medicine.umaryland.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Gottlieb, MD</last_name>
      <phone>410-328-8788</phone>
      <email>sgottlie@medicine.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Josephs Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Gottlieb</last_name>
      <phone>410-328-8788</phone>
      <email>sgottlie@medicine.umaryland.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>January 8, 2019</study_first_submitted>
  <study_first_submitted_qc>January 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>August 12, 2019</last_update_submitted>
  <last_update_submitted_qc>August 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, College Park</investigator_affiliation>
    <investigator_full_name>Steve Gottlieb</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>coronary artery bypass surgery</keyword>
  <keyword>ouabain</keyword>
  <keyword>acute kidney injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulin Fab Fragments</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

